

## Antigen presentation in EAE: role of microglia, macrophages and dendritic cells

Beatriz Almolda, Berta Gonzalez, Bernardo Castellano

Unit of Histology, Department of Cell Biology, Physiology and Immunology, Institute of Neuroscience. Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain

### TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Antigen presentation mechanism
4. Antigen presenting cells
5. Experimental autoimmune encephalomyelitis
6. Microglia, macrophages and monocytes in EAE
7. Microglia regulate the lymphocyte response
8. Dendritic cells in EAE: recruited from the periphery or derived from microglia?
9. Acknowledgements
10. References

### 1. ABSTRACT

Experimental autoimmune encephalomyelitis (EAE), a well-established model of multiple sclerosis, is characterised by microglial activation and lymphocytic infiltration. Lymphocytic activation through the antigen presentation process involves three main signals, the first provided by the engagement of major histocompatibility complex molecules (MHC) with the receptor of T-cells (TCR), the second by the binding of co-stimulatory molecules and the third by the secretion or expression of T-cell polarising molecules in specific populations of antigen presenting cells (APC). Microglial cells are considered to be the main APC population in the central nervous system (CNS). Specifically in EAE an increase in MHCs, co-stimulatory molecules and different T-cell polarising factors have been reported in microglia. However, a growing number of evidences suggest that dendritic cells (DCs), the main APC in the peripheral immune system, may also participate in the regulation of T-cell responses within the CNS. In this review we summarize the principal knowledge regarding microglial/macrophage function in EAE and their role in T-cell modulation, as well as the participation of DCs in the immune response associated to this disease.

### 2. INTRODUCTION

Microglial cells are considered to be the innate immune cell population in the central nervous system (CNS) (1-3). These cells originate from highly proliferative blood-borne myeloid cells infiltrating the brain parenchyma during foetal and early post-natal development to become amoeboid cells that, later, transform into the ramified microglial cells observed in adult animals (4-10). At least two subsets of microglial cells are nowadays recognised in adult CNS: 1) the so-called “resting” microglia, which are ramified cells distributed in all grey and white matter areas of the parenchyma, and 2) the so-called perivascular microglia (also called perivascular macrophages), which represent a minority population specifically located in the perivascular space of blood vessels (11). Ramified microglia are a permanent population of cells with a low turnover (12), with a very low CD45 expression and no expression of MHC-class II (13). In contrast, perivascular microglia/macrophages are periodically replaced (14), do not present the characteristic prolongations of microglia and express high levels of CD45, MHC-class II (15) and ED2 (16, 17). Due to their strategic location, these perivascular cells seem to play a key role in the initiation of immune responses in the CNS (11).

## Antigen presentation in EAE

Over the years, numerous studies have demonstrated the fundamental role played by microglial cells in the CNS, not only in normal conditions where they control tissue homeostasis (18, 19), but also in all of those situations in which the integrity of the tissue is disturbed, as a result of a wide variety of situations including lesions, neurotoxicity or infections (20-23). In these circumstances, microglial cells are activated, showing specific reactivity patterns that fully depend on changes that take place in the specific micro-environment where they are located as well as the magnitude and type of injury. The process of microglial reactivity involves changes in their gene activation and phenotype, manifested in morphological modifications, increase/decrease or *de novo* expression of surface molecules and secretion of a wide range of substances such as cytokines, chemokines and trophic factors (21, 22, 24-26). Nowadays, this great variety of changes, coupled with increasing evidence suggesting that different microglial subpopulations can co-exist within the CNS (27), indicates that microglial reactivity cannot be considered as homogeneous, but rather as a heterogeneous process that may have different outcomes according to where, how and what population of cells are activated.

Microglial cells not only interact with resident CNS cells as neurons or other glial cells, but are also able to establish a cross-talk with cells of the immune system that can be recruited to the CNS parenchyma under inflammatory conditions, through the production and secretion of the different molecules mentioned above. In particular, accumulating evidence *in vitro* and *in vivo* suggests that microglial cells may act as antigen presenting cells playing a role in the modulation of lymphocyte activation.

### 3. ANTIGEN PRESENTATION MECHANISM


Antigen processing and presentation is a crucial mechanism in the modulation of the immune response, by which foreign molecules or intracellular antigens are processed and presented for recognition by T cells, thereby inducing their activation. In general, intracellular antigens, such as those produced by viruses, defective self-molecules or tumour-associated antigens, are presented by the major histocompatibility complex class I (MHC-class I). In contrast, antigens from extracellular pathogens, such as bacteria, parasites and toxins, are presented in the context of MHC-class II molecules. Whereas all nucleated cells express MHC-class I, only specialised cells, the antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and B cells, in addition to expressing MHC-class I have the appropriate machinery for the processing and presentation of extracellular antigens through the MHC-class II molecules.

It has been shown that two main signals are involved in the mechanism of antigen presentation. The first signal is provided by the binding between MHC molecules bearing the antigen, with the receptor of T-cells (TCR) present on the surface of T-lymphocytes. This signal confers the specificity of the mechanism, as MHC-class I is specifically recognised by CD8+ T-lymphocytes, whereas

MHC-class II exclusively binds CD4+ T-cells. The second signal, the so-called co-stimulatory signal, is antigen-independent and is produced by the engagement of different receptors and their respective co-receptors expressed on the surface of both APCs and lymphocytes (28). The presence of these co-stimulatory signals has been demonstrated to be essential for the full activation of T-cells, as binding of the TCR with the MHCs in the absence of co-stimulation can lead to apoptosis or anergy of T-cells (29). Different combinations of co-stimulatory molecules providing stimulatory or inhibitory signals have been described (30). For example, the binding of ICOS, CD154 or OX40 with their corresponding ligands B7h, CD40 and OX40L delivers a stimulatory signal in lymphocytes, inducing their activation and proliferation, whereas the engagement of other co-stimulatory molecules like PD-1, with its receptor PD-L1, triggers an inhibitory signal causing the apoptosis of lymphocytes. Among the different co-stimulatory molecules currently described, the pair that plays a more relevant role in T-cell activation is the one formed by B7 molecules (B7.1 and B7.2, also known as CD80 and CD86), present in the APC surface and their receptors CD28 and CTLA-4 expressed in lymphocytes (31-34). Binding of B7.1 or B7.2 with CD28 generates a stimulatory signal in T-cells inducing their proliferation, expression of anti-apoptotic molecules and secretion of different cytokines. In contrast, the binding of B7.1 and B7.2 with CTLA-4 results in an inhibitory signal that mediates the stoppage in proliferation and cytokine secretion, leading to the end of the immune response (32, 35). Therefore, the delicate balance between positive and negative signals conducted by different co-stimulatory molecules may provide different outcomes of the immune response (See Figure 1 for a summary).

In addition to these two well-known signals, a growing body of evidence indicates the existence of a third type of signal by which APCs, particularly dendritic cells (DCs), may also regulate the immune response. This third signal consists of the expression of specific sets of T-cell polarising molecules either soluble or membrane-bound (see Figure 2). In general, Type 2 IFNs, IL12 and ICAM-1 are considered to be Th1 polarising molecules; IL4, MCP-1 and OX40L are Th2 polarising molecules; IL10, PD-L1 and ILT3/4 are viewed as regulatory T-cell polarising molecules; and TGF-beta and/or IL6 as polarising molecules for Th17 and inducible T-regulatory cells (36-38).

The selective expression profile of all of these polarising molecules is fully dependent on the signals that the DCs receive during their maturation process (Figure 2). The binding of pathogens to selective "pattern recognition receptors" or factors produced by tissue cells in response to these pathogens induce different signalling in immature DCs that promotes the specific expression and production of these polarising factors. Basically, DCs exposed to viruses or intracellular bacteria promote Th1 responses, some helminths induce Th2, and the presence of regulatory factors or specific pathogens such as *Schistosoma mansoni* support the development of T-regulatory cells (39).



**Figure 1.** Putative effects derived from the interaction between antigen presenting cells (APC) and T-cells.


#### 4. ANTIGEN PRESENTING CELLS

In general terms, it is assumed that those cell populations that have the capacity to process and present antigens and display them to T-cells are APCs. DCs are considered to be the most specialised APC type in the periphery. They are generated in the bone marrow and migrate as precursor cells to sites considered as potential points of entry for pathogens. Thus, there are subsets of resident DCs in the skin, in the gastrointestinal and respiratory tracts and in lymphoid organs which can be distinguished by the expression of different cell-surface markers that are not only dependent on the specific organ but also on the animal species (40-42). In steady-state situations, DCs display an immature phenotype (43, 44) characterised by: 1) expression of specific receptors and molecules such as Fc- and mannose-receptors whose presence confers to them a high capacity to phagocytose or endocytose antigens, and 2) high expression of MHC molecules, but low or absent expression of co-stimulatory or other molecules involved in T-cell activation. This phenotype renders these immature DCs able to process antigens but not to activate T-cells. Immature DCs are, however, not inactive cells but they rather continuously circulate through tissues and into lymph nodes capturing self-antigens as well as innocuous environmental proteins, playing an active role in the maintenance of tolerance (45). Under inflammatory conditions, immature DCs become activated and differentiate into mature DCs. This

maturation process involves the down-regulation of molecules related to the antigen capture and processing mechanism, and the up-regulation of the antigen presenting machinery, including an increase or *de novo* expression of co-stimulatory molecules (43). Moreover, mature DCs undergo changes in their expression pattern of chemokine receptors that allow them to migrate to the lymph nodes where they activate T-cells. For instance, DCs decrease molecules related to their tissue homing such as CCR5 and on the other hand, increase CCR7 expression, a molecule involved in their migration to the nearest lymph node.

In addition to DCs, macrophages and B-lymphocytes can also act as APCs (46). They are considered non-professional APCs because, in contrast to the professional DCs, they cannot activate naïve T-cells and they do not express MHCs constitutively. Nevertheless, they have the necessary machinery to capture and process antigens, and under inflammatory conditions they increase MHC expression, becoming able to activate T-cells.

For many years it has been assumed that there were not DCs in the CNS. This, together with the presence of the blood brain barrier, the lack of lymphatic vessels and the fact that skin grafts, viruses, bacterias or antigens directly inoculated in the parenchyma do not induce an immune response (47-50), contributes to the initial views of the CNS as an immune-isolated site. In this context, microglial cells were considered to be incompetent immune



**Figure 2.** Summary of signals leading to the maturation of immature dendritic cells (DCs) into different subtypes of mature DCs. These mature DCs secrete different T-cell polarising molecules that regulate the transformation of T-naïve cells into T-effector cells.

cells. However, during the last decade, the capacity of microglial cells to interact with immune cells recruited into the CNS parenchyma under several situations has been widely reported (3, 23, 51, 52), suggesting that microglia may be considered as being APCs in the CNS and under certain circumstances they differentiate into DC-like cells. Furthermore, as shall be discussed in detail later, in addition to DCs of a microglial origin, an increasing number of evidence suggests that specific subpopulations of bone marrow-derived DCs may reach the CNS parenchyma under certain inflammatory conditions, such as focal cortical ischemia (53), stroke (54), excitotoxic lesion (55), delayed type-hypersensitivity lesions (56) or experimental autoimmune encephalomyelitis (15, 56).

## 5. EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

One of the most useful animal models for the study of the interactions established between CNS resident and peripheral immune cells is experimental autoimmune encephalomyelitis (EAE), which is a commonly used model of human multiple sclerosis (MS) although it may

not represent all pathophysiological aspects of the human disease. EAE is characterised by progressive muscle weakness and paralysis starting in the tail and hindlimbs and may eventually lead to paraplegia or even tetraplegia. Associated with this clinical symptomatology, animals induced with EAE experience a progressive and significant loss of weight, mimicking what also happens in MS. There are several models of EAE with particular symptomatological and histopathological features that reproduce different forms of human MS (57, 58). Thus there are models, such as that induced by myelin oligodendrocyte protein (MOG) immunisation in C57BL/6 mice, which resemble a form of chronic MS; others, such as that induced in SJL mice by proteolipid protein (PLP) injection, which reproduce relapsing-remitting MS, which alternate stages of paralysis with stages of recovery, and also some models like that caused in Lewis rats by myelin basic protein (MBP) immunisation, which mimic an acute phase of MS characterised by a single peak of disability followed by a full and spontaneous recovery. Multiple factors including the species, strain, sex and age of animals used, as well as the peptide and the protocol utilised in the immunization process, seem to be crucial to yield the

## Antigen presentation in EAE

specific type of EAE. Susceptible animals, mainly rodents, can be induced by: 1) active immunisation, which consists of the subcutaneous injection of an emulsion containing nervous tissue or any peptide of myelin proteins together with a coadjuvant, or 2) passive immunisation, based on the intravenous injection of T-lymphocytes activated against myelin proteins.

EAE primarily affects the white matter of the spinal cord although today it has also been reported that the spinal cord grey matter and other CNS areas such as the cerebellum and the brainstem are affected (59, 60). As occurs in human MS, the main histopathological features of EAE are glial reactivity, mainly microglial activation, and a large infiltration of peripheral immune cells, principally T-cells (3, 24, 61). Due to the autoimmune nature of EAE and MS, it was widely accepted that CD4+ T cells with a Th1 pro-inflammatory phenotype were the principal lymphocytes involved in the disease (62). Over the last few years, however, the identification of different subsets of lymphocytes with varied functions and cytokine profiles (63-65), have led to the re-evaluation of this initial assumption. It has been demonstrated that Th17 lymphocytes, a subtype of CD4+ T-cells (66, 67), are able to induce EAE when injected into mice (68). It has also been shown that Th17 cells are present in the spinal cord at the onset of EAE in mice (69), suggesting a pathogenic role of these lymphocytes. On the other hand, subtypes of regulatory cells, such as the extensively studied Foxp3 T-regulatory cells (Treg), are also reported in EAE. Treg cells have been detected during recovery in mice (70-72), and their beneficial role in EAE has been clearly demonstrated (71, 73, 74). Furthermore, in addition to CD4+ T-cells, some authors have also suggested the participation of other types of lymphocytes, such as CD8+ T-cells and gamma-delta T-cells (75-78).

## 6. MICROGLIA, MACROPHAGES AND MONOCYTES IN EAE

Microglial reactivity has been reported in different models of EAE (79-85). The major part of these studies has focused on the peak of the disease, where maximal levels of microglial activation were found. However, only few reports have analysed the temporal pattern of microglial reactivity along the course of EAE. Specifically in acute EAE, microglial reactivity has been detected in close correspondence with the increase in clinical symptomatology along the inductive and peak phases of the disease (85). Despite the large amount of literature describing microglial reactivity in EAE and human MS, the exact function played by these cells in these diseases still remains to be established. On the one hand, the observations of maximal microglial reactivity at the peak of the disease, together with the fact that the decrease in microglial reactivity, induced by treatments such as macrophage inhibitor factor (MIF) (86) and MW01-5-188WH (87) or observed in microglia-depleted animals (88), has been associated with beneficial effects in EAE, led to the perception of microglia as detrimental cells in EAE pathogenesis. Moreover, it has been reported that activated microglia can release a wide range of molecules

such as cytokines, chemokines and nitric oxide which may contribute to the recruitment of immune cells and the spread of the inflammatory response in the CNS (2, 24).

On the other hand, it has also been reported that during EAE remissions, despite the gradual recovery of animals, microglial cells remained very reactive in both mice (84) and rat EAE models (85), suggesting a putative beneficial role of these microglial cells. Microglial reactivity has also been described in EAE-resistant rats (89) and in normal-appearing white matter in human MS (90). Furthermore, earlier recovery from EAE symptoms has been reported in mice administered with tufsin, a microglial/macrophage activator (86). In this sense, the capacity of microglial cells to also produce protective factors such as anti-inflammatory cytokines, prostanoids and trophic factors that may contribute to the termination of the inflammatory response in the CNS, has been extensively demonstrated (2, 24).

In addition to morphological changes, an increase in the number of reactive microglia/macrophage cells in both chronic (81) and acute EAE (85) has been reported. This increase could be due to resident microglial cell proliferation or it could be the result of the recruitment of blood-borne monocytes, a population whose infiltration along the course of EAE has been described (91-93). The lack of good markers to distinguish between macrophages coming from the monocytic lineage and reactive macrophage-like microglial cells makes the analysis of the contribution of infiltrated monocytes to the final number of microglial/macrophage cells difficult.

Some evidence indicates that besides microglia, the perivascular macrophage population may also play a role in the pathogenesis of EAE. They are commonly distinguished from microglial cells by their specific expression of ED2 in rats (16) and its counterpart CD163 in humans (17). Data in the acute EAE model induced in Lewis rat has reported an increase in the number of ED2+ cells before the appearance of clinical signs (94), which is in close relationship with the progressive increase in EAE symptomatology (85). Moreover, these ED2+ cells infiltrate the CNS parenchyma specifically at the peak of the disease (85). Due to their strategic location and their constitutive expression of MHC-class II (15), perivascular macrophages seem to be involved in the initiation of the immune response associated with EAE, perhaps contributing to T-cell activation, a step required for the subsequent infiltration of T-cells into the parenchyma (95, 96). Indeed, experimental evidence based on the selective elimination of perivascular macrophages by the use of chlorodate liposomes (97) revealed that their depletion produced a decrease in the symptomatology (94), reinforcing the idea of an active participation of these cells in EAE evolution.

## 7. MICROGLIA REGULATE THE LYMPHOCYTE RESPONSE

Infiltration and retention of T-cells in the CNS requires their interaction with local APCs (95, 96). As

## Antigen presentation in EAE

microglial cells are currently considered to be the principal APC within the CNS parenchyma (2, 24), it is assumed that, in the CNS, they may play a key role in modulating the lymphocyte response including their proliferation, differentiation and apoptosis through the antigen presenting mechanism. Although in basal conditions, microglia do not express MHC-class I and MHC-class II, it has been shown that once activated they can rapidly express these molecules in a variety of situations (1, 98).

Specifically in EAE, it has been widely reported that when microglial cells become activated, they increase the expression of MHC molecules in both mouse (81, 99-101) and rat models (102-106). The role played by these MHC molecules in EAE showed controversial results. On the one hand, some studies pointed towards a detrimental role, as it has been reported that some treatments with a positive effect in EAE were associated with a decrease in MHC-class II expression (107, 108). However, on the other hand, a growing number of evidence indicated a putative beneficial effect of these molecules. It has been shown that MHC-class I KO mice present aggravation of EAE symptoms (109, 110) and MHC-class II KO showed impairment of remyelination after Theiler's murine encephalomyelitis (111). Interestingly, in the acute EAE model induced in Lewis rats, the expression of both MHC-class I and class II molecules increased progressively during the inductive and peak phases correlating with the increase in clinical symptomatology, but levels of MHC expression remained high during the spontaneous recovery phase, even in animals that completely recovered and do not show any symptomatology (15).

At this point, it is important to highlight that MHC expression *per se* is not sufficient for antigen presentation, and co-stimulatory signals are necessary for the complete activation of T-cells (28, 31). The involvement of co-stimulatory molecules in EAE evolution comes principally from studies showing the effects of the absence of these co-stimulatory molecules (112). Thus, a reduction of EAE severity has been correlated with the blockage of CD28 (113, 114) or B7 (115, 116), whereas the blockage of CTLA-4, the co-stimulatory signal that drives the ending of the immune responses, has been shown to produce a worsening of the disease (117).

The question of whether a specific pattern of MHC and co-stimulatory molecule expression governs the evolution of EAE remains unresolved, and so far it is not clearly known which are the cells that express these molecules. Differences in the expression of B7.1 and B7.2 have been detected among different models of EAE. Whereas in mouse models B7.1 has been commonly described during the relapses, being nominated as one of those responsible for the epitope-spreading phenomenon and the induction of clinical relapses (115, 118-120), no B7.1 expression has been detected at any phase of acute EAE in rats (15). In fact, in this acute EAE model, despite the high expression of MHC molecules in microglia and the infiltration of CD28<sup>+</sup> T-cells, neither B7.1 nor B7.2 expression was found during the inductive and peak phases (15), leading the authors to suggest that this expression of

MHCs without a concomitant co-stimulatory signal can mediate either the anergy or the apoptosis of infiltrating T-cells, as described in the peripheral immune system (29). Induction of T-cell anergy or apoptosis may, therefore, be the cause of the immune response resolution leading to the spontaneous clinical recovery (15). In fact, apoptosis of encephalitogenic T-lymphocytes has been widely described in EAE models (121-124).

In contrast, during the recovery phase the aforementioned study (15) revealed the expression of B7.2 in a subpopulation of microglial cells located in the vicinity of blood vessels. This pattern of expression of MHCs with B7.2, in the absence of B7.1, has been reported in reactive microglia in acute CNS injuries, such as facial-nerve axotomy (125), entorhinal-cortex lesion (126, 127) and cuprizone-induced demyelination (128), situations in which myelin destruction does not lead to autoimmunity. Furthermore, B7.2 expression has been described accompanied by an accumulation of cells expressing CTLA-4 (15), which is the B7.2 co-receptor that inhibits T-cell activation (129). CTLA-4 was found constitutively expressed in T-regulatory cells (130), a specialised subpopulation of T-lymphocytes that suppressed the activation of the immune system, whose principal function is the maintenance of immunological homeostasis and tolerance to autoantigens (For detailed reviews, see (131-133)). The role played by CTLA-4 in T-reg activation is still not fully determined. However, it has been shown that signaling through this co-stimulatory molecule is necessary for the induction of Foxp3, the master transcription factor of Treg (134, 135), and for the activation of this population of lymphocytes (135-137).

Finally, it is also important to mention that an increasing number of reports suggests the involvement of other co-stimulatory molecules in EAE progression (138). CD40/CD40L molecules have been described in MS plaques in humans (139) and during relapses in mice with EAE (118). It has been shown that CD40/CD40L recognition is instrumental in the development of EAE, since EAE induction is prevented in CD40KO mice or by treatment of wildtype mice with antibodies to CD40L (139, 140). Other molecules whose expression has been involved in EAE are PD1/PDL1,2 and ICOS/ICOS-L. The involvement of PD1 and its receptors PDL1 and PDL2, in EAE, came from studies showing the upregulation of these molecules at the peak of the disease (141, 142). Some years later, the use of KO mice demonstrated that a deficiency in either PD1 or PDL1, but not PDL2, induces an increase in EAE severity (143), suggesting a putative beneficial role of this signalling in EAE progression. Moreover, recently it has been shown that EAE can be induced in PD1-deficient mice without the use of pertussis toxin (PTX), whereas in wild-type animals, PTX administration is essential for EAE development (144). Only few studies have addressed the role of signalling through ICOS and ICOS-L. These molecules may exert a beneficial role, as induction of EAE in ICOS-deficient mice results in severe disease (145). Nonetheless, treatment with anti-ICOS antibody suggested a dual role of ICOS in EAE: treatment during the first days post-induction (1-10 days post-induction) exacerbated EAE

## Antigen presentation in EAE

severity, whereas administration during the effector phase (9-20 days post-induction) promotes a delay in onset and severity (146). However, no reports about ICOS expression in microglia or any other CNS resident cells are currently available.

### 8. DENDRITIC CELLS IN EAE: RECRUITED FROM THE PERIPHERY OR DERIVED FROM MICROGLIA?

Different subtypes of DCs showing specific expression of surface molecules are currently identified in both human and mouse (41, 147). They are continuously produced from stem cells located in the bone marrow and they migrate as DC-precursor cells to peripheral organs where they differentiate into specific populations of resident DCs, by the action of different factors such as GM-CSF (granulocyte-macrophage colony stimulating factor), Flt-3 and c-Kit, in an antigen-independent manner (148).

The presence of DCs within the CNS has been an issue of debate for many years. Nowadays the presence of these cells in selective areas of the healthy CNS, such as the meninges and the choroids plexus, is accepted (149, 150). Studies in recent years have reported the existence of specific populations of DCs within the brain parenchyma under inflammatory conditions (151, 152).

The presence of DCs within the CNS parenchyma in different models of EAE in rat (15, 56) and mouse (153-155) has been reported. The role played by DCs in the evolution of EAE is still controversial. Some authors point towards a detrimental role showing that intracerebral injection of DCs, pulsed *in vitro* with MOG, exacerbates EAE pathology (156). In addition, it has been reported that DCs are responsible for the immune infiltration in EAE (157) and promote the polarisation of lymphocytes towards Th17-pathogenic cells (155). However, some studies have reported that if DCs were previously cultured with TNF-alpha, a tolerogenic phenotype would be induced in these cells which, when injected, produced a decrease in EAE symptomatology (156, 158). These results suggest a beneficial role of DCs and indicate that further research is needed to clarify the exact role of DCs in CNS (159). In addition, the emergence of new subsets of DCs with regulatory cues, such as the tolerogenic DCs, opens new perspectives in the study of CNS DCs. Tolerogenic DCs are considered as an incomplete or modulated form of DC maturation, involved in peripheral tolerance via induction of anergy, apoptosis or Treg activation (160, 161). *In vitro* studies have demonstrated that certain cytokines such as IL10 and TGF-beta, some vitamins (1,25-dihydroxy vitamin D3, vitamin C), immunosuppressive treatments using glucocorticoids or NFkB inhibitors can generate a tolerogenic phenotype in DCs (162). In contrast to immature DCs, also considered as inductors of tolerance, tolerogenic DCs display a stable phenotype, which is resistant to further maturation. Characteristic features of these tolerogenic DCs have been described including the secretion of the anti-inflammatory enzyme indoleamine 2,3-dioxygenase (IDO), expression of MHC molecules but low levels of co-stimulatory molecules

and expression of surface molecules involved in T-cell inhibition such as PDL1 or CD95L (163). All of these molecules contribute to the inhibition of T-cell proliferation and induction of apoptosis. Despite the large amount of information in the peripheral immune system on the phenotype, role and modulation of these tolerogenic DCs, little is known regarding the presence and participation of these cells in the CNS during EAE. Some evidence, nevertheless, raises the possibility that tolerogenic DCs can be involved in EAE evolution. The expression of IDO in EAE has been described in mouse, coinciding with the remission phase (164). IL10 and TGF-beta expression have also been detected during the remission stage (165, 166). Moreover, low levels of co-stimulatory molecules have been detected in acute EAE (15).

Another issue that remains to be elucidated is what the origin and the differentiation cues of CNS DCs are. Two different theories can be considered to explain the possible sources of these cells: differentiation from resident microglial cells or recruitment from the periphery. Regarding the putative microglial origin, *in vitro* studies have demonstrated the capacity of microglial cells to differentiate into cells with a DC phenotype after exposure to GM-CSF (13, 154). In addition, recent studies have shown the existence of a subpopulation of microglial cells that constitutively displayed CD11c in the healthy brain (167). In accordance with these observations, the expression of CD1, a marker commonly used for the identification of immature DCs (168), has been demonstrated in a subpopulation of microglial cells located in the vicinity of blood vessels during the course of EAE (15). In agreement with this idea, an increase in CD1 expression in CD11b+CD45low microglial cells and CD11b+CD45high macrophages has been reported during the peak of EAE in mouse by flow cytometry (169). If this theory of the microglial origin of DCs were true, microglial cells should be considered as a population of immature DCs residing in the CNS parenchyma, as already suggested by some authors (170).

Alternatively, it has also been proposed that CNS DCs can be recruited from the periphery. Although monocytes were initially described as the precursors of all of the subpopulations of tissue macrophages, it is now recognised that they can also differentiate into DCs. In steady-state conditions, monocytes are the precursor of tissue-resident DCs such as the Langerhans cells in the skin, but under inflammatory situations the differentiation of monocytes into monocyte-derived DCs has recently been described (171). The choice of monocytes to differentiate into DCs or macrophages is likely determined by the cytokine milieu and the signals that these cells received from the environment (172). The presence of Ly6C+ monocytes, the putative source of monocyte-DCs, has been recently reported in EAE in mouse (92, 173). Reinforcing the idea of a putative peripheral origin of the CNS DC population, recent findings have revealed the presence of a specific population of mature DCs, which does not correspond to microglia, within the CNS parenchyma (15). These mature DCs were characterised by the expression of fascin, an actin-bundling protein whose expression has been linked to DC maturation (174-176).

## Antigen presentation in EAE

Taking into consideration all of these observations, the origin and function of DCs in CNS remain to be clarified and further research is warranted.

### 9. ACKNOWLEDGMENTS

The authors would like to thank Isabella Appiah for her comments and Mr Chuck Simmons, a native, English-speaking Instructor of English at the Autonomous University of Barcelona for the proofreading of this manuscript. This work was supported by the Fundacio MaratoTV3, Fundacion Alicia Koplowitz and Spanish Ministry of Science and Innovation (BFU2008-04407/BFI).

### 10. REFERENCES

1. Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. *Trends Neurosci* 19, 312-8 (1996)
2. Aloisi F: Immune function of microglia. *Glia* 36, 165-79 (2001)
3. Carson MJ: Microglia as liaisons between the immune and central nervous systems: functional implications for multiple sclerosis. *Glia* 40, 218-31 (2002)
4. Ling EA: Transformation of monocytes into amoeboid microglia in the corpus callosum of postnatal rats, as shown by labelling monocytes by carbon particles. *J Anat* 128, 847-58 (1979)
5. Ling EA, D Penney, CP Leblond: Use of carbon labeling to demonstrate the role of blood monocytes as precursors of the 'amoeboid cells' present in the corpus callosum of postnatal rats. *J Comp Neurol* 193, 631-57 (1980)
6. Ling EA: The origin and nature of microglia. In: *Advances in Cellular Neurobiology*. Eds: S Federof, L Hertz. Academic Press, New York (1981)
7. Ling EA, W C Wong: The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. *Glia* 7, 9-18 (1993)
8. Dalmau I, B Finsen, N Tonder, J Zimmer, B Gonzalez, B Castellano: Development of microglia in the prenatal rat hippocampus. *J Comp Neurol* 377, 70-84 (1997)
9. Kaur C, AJ Hao, CH Wu, EA Ling: Origin of microglia. *Microsc Res Tech* 54, 2-9 (2001)
10. Dalmau I, JM Vela, B Gonzalez, B Finsen, B Castellano: Dynamics of microglia in the developing rat brain. *J Comp Neurol* 458, 144-57 (2003)
11. Williams K, X Alvarez, AA Lackner: Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. *Glia* 36, 156-64 (2001)
12. Lawson LJ, VH Perry, S Gordon: Turnover of resident microglia in the normal adult mouse brain. *Neuroscience* 48, 405-15 (1992)
13. Santambrogio L, SL Belyanskaya, FR Fischer, B Cipriani, CF Brosnan, P Ricciardi-Castagnoli, LJ Stern, JL Strominger, R Riese: Developmental plasticity of CNS microglia. *Proc Natl Acad Sci U S A* 98, 6295-300 (2001)
14. Bechmann I, E Kwidzinski, AD Kovac, E Simburger, T Horvath, U Gimsa, U Dirnagl, J Priller, R Nitsch: Turnover of rat brain perivascular cells. *Exp Neurol* 168, 242-9 (2001)
15. Almolda B, B Gonzalez, B Castellano: Activated microglial cells acquire an immature dendritic cell phenotype and may terminate the immune response in an acute model of EAE. *J Neuroimmunol* 223, 39-54 (2010)
16. Dijkstra CD, EA Dopp, TK van den Berg, JG Damoiseaux: Monoclonal antibodies against rat macrophages. *J Immunol Methods* 174, 21-3 (1994)
17. Fabriek BO, ES Van Haastert, I Galea, MM Polfliet, ED Dopp, MM Van Den Heuvel, TK Van Den Berg, CJ De Groot, P Van Der Valk, CD Dijkstra: CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. *Glia* 51, 297-305 (2005)
18. Davalos D, J Grutzendler, G Yang, JV Kim, Y Zuo, S Jung, DR Littman, ML Dustin, WB Gan: ATP mediates rapid microglial response to local brain injury *in vivo*. *Nat Neurosci* 8, 752-8 (2005)
19. Nimmerjahn A, F Kirchhoff, F Helmchen: Resting microglial cells are highly dynamic surveillants of brain parenchyma *in vivo*. *Science* 308, 1314-8 (2005)
20. Garden GA, T Moller: Microglia biology in health and disease. *J Neuroimmune Pharmacol* 1, 127-37 (2006)
21. Dheen ST, C Kaur, EA Ling: Microglial activation and its implications in the brain diseases. *Curr Med Chem* 14, 1189-97 (2007)
22. Hanisch UK, H Kettenmann: Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nat Neurosci* 10, 1387-94 (2007)
23. Graeber MB, WJ Streit: Microglia: biology and pathology. *Acta Neuropathol* 119, 89-105 (2010)
24. Raivich G, R Banati: Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. *Brain Res Brain Res Rev* 46, 261-81 (2004)
25. Chew LJ, A Takanohashi, M Bell: Microglia and inflammation: impact on developmental brain injuries. *Ment Retard Dev Disabil Res Rev* 12, 105-12 (2006)

## Antigen presentation in EAE

26. Ransohoff RM, VH Perry: Microglial physiology: unique stimuli, specialized responses. *Annu Rev Immunol* 27, 119-45 (2009)
27. Carson MJ, TV Bilousova, SS Puntambekar, B Melchior, JM. Doose, IM Ethell: A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease. *Neurotherapeutics* 4, 571-9 (2007)
28. Lanzavecchia A: Understanding the mechanisms of sustained signaling and T cell activation. *J Exp Med*, 185, 1717-9 (1997)
29. Kishimoto H, J Sprent: Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells. *J Immunol* 163, 1817-26 (1999)
30. Nurieva RI, X Liu, C Dong: Yin-Yang of costimulation: crucial controls of immune tolerance and function. *Immunol Rev* 229, 88-100 (2009)
31. Lenschow DJ, TL Walunas, JA Bluestone: CD28/B7 system of T cell costimulation. *Annu Rev Immunol* 14, 233-58 (1996)
32. Sansom DM: CD28, CTLA-4 and their ligands: who does what and to whom? *Immunology* 101, 169-77 (2000)
33. Salomon B, JA Bluestone: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. *Annu Rev Immunol* 19, 225-52 (2001)
34. Sharpe AH, GJ Freeman: The B7-CD28 superfamily. *Nat Rev Immunol* 2, 116-26 (2002)
35. Karandikar NJ, CL Vanderlugt, TL Walunas, SD Miller, JA Bluestone: CTLA-4: a negative regulator of autoimmune disease. *J Exp Med* 184, 783-8 (1996)
36. de Jong EC, HH Smits, ML Kapsenberg: Dendritic cell-mediated T cell polarization. *Springer Semin Immunopathol* 26, 289-307 (2005)
37. Mangan PR, LE Harrington, DB O'Quinn, WS Helms, DC Bullard, CO Elson, RD Hatton, SM Wahl, TR Schoeb, CT Weaver: Transforming growth factor-beta induces development of the T (H)17 lineage. *Nature* 441, 231-4 (2006)
38. Bettelli E, Y Carrier, W Gao, T Korn, TB Strom, M Oukka, HL Weiner, VK Kuchroo: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature* 441, 235-8 (2006)
39. Kapsenberg ML: Dendritic-cell control of pathogen-driven T-cell polarization. *Nat Rev Immunol* 3, 984-93 (2003)
40. Miranda de Carvalho C, C Bonnefont-Rebeix, D Rigal, L Chabanne: "Dendritic cells in different animal species: an overview". *Pathol Biol (Paris)* 54, 85-93 (2006)
41. Sato K & S Fujita: Dendritic cells: nature and classification. *Allergol Int* 56, 183-91 (2007)
42. Heath WR, FR Carbone: Dendritic cell subsets in primary and secondary T cell responses at body surfaces. *Nat Immunol* 10, 1237-44 (2009)
43. Banchereau J, RM Steinman: Dendritic cells and the control of immunity. *Nature* 392, 245-52 (1998)
44. Banchereau J, F Briere, C Caux, J Davoust, S Lebecque, YJ Liu, B Pulendran, K Palucka: Immunobiology of dendritic cells. *Annu Rev Immunol* 18, 767-811 (2000)
45. Steinman RM, D Hawiger, K Liu, L Bonifaz, D Bonnyay, K Mahnke, T Iyoda, J Ravetch, M Dhodapkar, K Inaba, M Nussenzweig: Dendritic cell function *in vivo* during the steady state: a role in peripheral tolerance. *Ann N Y Acad Sci* 987, 15-25 (2003)
46. Hume DA: Macrophages as APC and the dendritic cell myth. *J Immunol* 181, 5829-35 (2008)
47. Medawar PB: Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. *Br J Exp Pathol* 29, 58-69 (1948)
48. Barker CF, RE Billingham: Immunologically privileged sites. *Adv Immunol* 25, 1-54 (1977)
49. Stevenson PG, S Hawke, DJ Sloan, CR Bangham: The immunogenicity of intracerebral virus infection depends on anatomical site. *J Virol* 71, 145-51 (1997)
50. Matyszak MK, VH Perry: Bacillus Calmette-Guerin sequestered in the brain parenchyma escapes immune recognition. *J Neuroimmunol* 82, 73-80 (1998)
51. Aloisi F, B Serafini, L Adorini: Glia-T cell dialogue. *J Neuroimmunol* 107, 111-7 (2000)
52. Deng X, S Sriram: Role of microglia in multiple sclerosis. *Curr Neurol Neurosci Rep* 5, 239-44 (2005)
53. Reichmann G, M Schroeter, S Jander, HG Fischer: Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. *J Neuroimmunol* 129, 125-32 (2002)
54. Kostulas N, HL Li, BG Xiao, YM Huang, V Kostulas, H Link: Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. *Stroke* 33, 1129-34 (2002)
55. Newman TA, I Galea, N van Rooijen, VH Perry: Blood-derived dendritic cells in an acute brain injury. *J Neuroimmunol* 166, 167-72 (2005)

## Antigen presentation in EAE

56. Matyszak MK, VH Perry: The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. *Neuroscience* 74, 599-608 (1996)
57. Teixeira SA, AA Varriano, SM Bolonheis, MN Muscará: Experimental autoimmune encephalomyelitis: A heterogeneous group of animal models to study human multiple sclerosis. *Drug Discovery Today: Disease Models* 2, 127-134 (2005)
58. Wekerle H, FC Kurschus: Animal models of multiple sclerosis. *Drug Discovery Today: Disease Models* 3, 359-367 (2006)
59. Chin CL, M Pai, PF Bousquet, AJ Schwartz, EM O'Connor, CM Nelson, VP Hradil, BF Cox, BL McRae, GB Fox: Distinct spatiotemporal pattern of CNS lesions revealed by USPIO-enhanced MRI in MOG-induced EAE rats implicates the involvement of spino-olivocerebellar pathways. *J Neuroimmunol* 211, 49-55 (2009)
60. MacKenzie-Graham A, MR Tinsley, KP Shah, C Aguilar, LV Strickland, J Boline, M Martin, L Morales, DW Shattuck, RE Jacobs, RR Voskuhl, AW. Toga: Cerebellar cortical atrophy in experimental autoimmune encephalomyelitis. *Neuroimage* 32, 1016-23 (2006)
61. Engelhardt B, RM Ransohoff: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. *Trends Immunol* 26, 485-95 (2005)
62. Kuchroo VK, AC Anderson, H Waldner, M Munder, E Bettelli, LB Nicholson: T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. *Annu Rev Immunol* 20, 101-23 (2002)
63. Reinhardt RL, SJ Kang, HE Liang, RM Locksley: T helper cell effector fates--who, how and where? *Curr Opin Immunol* 18, 271-7 (2006)
64. Dittel BN: CD4 T cells: Balancing the coming and going of autoimmune-mediated inflammation in the CNS. *Brain Behav Immun* 22, 421-30 (2008)
65. Takatori H, Y Kanno, Z Chen, JJ O'Shea: New complexities in helper T cell fate determination and the implications for autoimmune diseases. *Mod Rheumatol* 18, 533-41 (2008)
66. Harrington LE, PR Mangan, CT Weaver: Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Curr Opin Immunol* 18, 349-56 (2006)
67. Aranami T, T Yamamura: Th17 Cells and autoimmune encephalomyelitis (EAE/MS). *Allergol Int* 57, 115-20 (2008)
68. Jager A, V Dardalhon, RA Sobel, E Bettelli, VK Kuchroo: Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. *J Immunol* 183, 7169-77 (2009)
69. Murphy AC, SJ Lalor, MA Lynch, KH Mills: Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. *Brain Behav Immun* 24, 641-51 (2010)
70. Kohm AP, PA Carpentier, HA Anger, SD Miller: Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. *J Immunol* 169, 4712-6 (2002)
71. McGeachy MJ, LA Stephens, SM Anderton: Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. *J Immunol* 175, 3025-32 (2005)
72. Korn T, AC Anderson, E Bettelli, M Oukka: The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. *J Neuroimmunol* 191, 51-60 (2007)
73. Zhang X, DN Koldzic, L Izikson, J Reddy, RF Nazareno, S Sakaguchi, VK Kuchroo, HL Weiner: IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. *Int Immunol* 16, 249-56 (2004)
74. Kohm AP, JS McMahon, JR Podojil, WS Begolka, M DeGutes, DJ Kaspruwicz, SF Ziegler, SD Miller: Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. *J Immunol* 176, 3301-5 (2006)
75. Sun D, JN Whitaker, Z Huang, D Liu, C Coleclough, H Wekerle, CS Raine: Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. *J Immunol* 166, 7579-87 (2001)
76. Huseby ES, D Liggitt, T Brabb, B Schnabel, C Ohlen, J Goverman: A pathogenic role for myelin-specific CD8 (+) T cells in a model for multiple sclerosis. *J Exp Med* 194, 669-76 (2001)
77. Ford ML, BD Evavold: Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. *Eur J Immunol* 35, 76-85 (2005)
78. Wohler JE, SS Smith, SR Barnum: gammadelta T cells: the overlooked T-cell subset in demyelinating disease. *J Neurosci Res* 88, 1-6 (2010)
79. Matsumoto Y, K Ohmori, M Fujiwara: Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system. *J Neuroimmunol* 37, 23-33 (1992)

## Antigen presentation in EAE

80. Gehrman J, R Gold, C Linington, J Lannes-Vieira, H Wekerle, GW Kreutzberg: Microglial involvement in experimental autoimmune inflammation of the central and peripheral nervous system. *Glia* 7, 50-9 (1993)
81. Ponomarev ED, LP Shriver, K Maresz, BN Dittel: Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. *J Neurosci Res* 81, 374-89 (2005)
82. Craner MJ, TG Damarjian, S Liu, BC Hains, AC Lo, JA Black, J Newcombe, ML Cuzner, SG Waxman: Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. *Glia* 49, 220-9 (2005)
83. Brown DA, PE Sawchenko: Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. *J Comp Neurol* 502, 236-60 (2007)
84. Rasmussen S, Y Wang, P Kivisakk, RT Bronson, M Meyer, J Imitola, SJ Khoury: Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing-remitting experimental autoimmune encephalomyelitis. *Brain* 130, 2816-29 (2007)
85. Almolda B, M Costa, M Montoya, B Gonzalez, B Castellano: CD4 microglial expression correlates with spontaneous clinical improvement in the acute Lewis rat EAE model. *J Neuroimmunol* 209, 65-80 (2009)
86. Bhasin M, M Wu, SE Tsirka: Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis. *BMC Immunol* 8, 10 (2007)
87. Guo X, K Nakamura, K Kohyama, C Harada, HA Behanna, DM Watterson, Y Matsumoto, T Harada: Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. *Neurosci Res* 59, 457-66 (2007)
88. Heppner FL, M Greter, D Marino, J Falsig, G Raivich, N Hovelmeyer, A Waisman, T Rulicke, M Prinz, J Priller, B Becher, A Aguzzi: Experimental autoimmune encephalomyelitis repressed by microglial paralysis. *Nat Med* 11, 146-52 (2005)
89. Mensah-Brown EP, A Shahin, LJ Garey, ML Lukic: Neuroglial response after induction of experimental allergic encephalomyelitis in susceptible and resistant rat strains. *Cell Immunol* 233, 140-7 (2005)
90. Gay F: Activated microglia in primary MS lesions: defenders or aggressors? *Int MS J* 14, 78-83 (2007)
91. Floris S, EL Blezer, G Schreibelt, E Dopp, SM van der Pol, IL Schadee-Eestermans, K Nicolay, CD Dijkstra, HE de Vries: Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. *Brain* 127, 616-27 (2004)
92. Zhu B, Y Bando, S Xiao, K Yang, AC Anderson, VK Kuchroo, SJ Khoury: CD11b+Ly-6C (hi) suppressive monocytes in experimental autoimmune encephalomyelitis. *J Immunol* 179, 5228-37 (2007)
93. Ifergan I, H Kebir, M Bernard, K Wosik, A Dodelet-Devillers, R Cayrol, N Arbour, A Prat: The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. *Brain* 131, 785-99 (2008)
94. Polfliet MM, F van de Veerdonk, EA Dopp, EM van Kesteren-Hendriks, N van Rooijen, CD Dijkstra, TK van den Berg: The role of perivascular and meningeal macrophages in experimental allergic encephalomyelitis. *J Neuroimmunol* 122, 1-8 (2002)
95. Kawakami N, S Lassmann, Z Li, F Odoardi, T Ritter, T Ziemssen, WE Klinkert, JW Ellwart, M Bradl, K Krivacic, H Lassmann, RM Ransohoff, HD Volk, H Wekerle, C Linington, A Flugel: The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. *J Exp Med*, 199, 185-97 (2004)
96. Archambault AS, J Sim, MA Gimenez, JH Russell: Defining antigen-dependent stages of T cell migration from the blood to the central nervous system parenchyma. *Eur J Immunol* 35, 1076-85 (2005)
97. Polfliet MM, PH Goede, EM van Kesteren-Hendriks, N van Rooijen, CD Dijkstra, TK van den Berg: A method for the selective depletion of perivascular and meningeal macrophages in the central nervous system. *J Neuroimmunol* 116, 188-95 (2001)
98. Perry VH: A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation. *J Neuroimmunol* 90, 113-21 (1998)
99. Lindsey JW, L Steinman: Competitive PCR quantification of CD4, CD8, ICAM-1, VCAM-1, and MHC class II mRNA in the central nervous system during development and resolution of experimental allergic encephalomyelitis. *J Neuroimmunol* 48, 227-34 (1993)
100. Pope JG, CL Vanderlugt, SM Rahbe, HL Lipton, SD Miller: Characterization of and functional antigen presentation by central nervous system mononuclear cells from mice infected with Theiler's murine encephalomyelitis virus. *J Virol* 72, 7762-71 (1998)
101. Juedes AE, NH Ruddle: Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. *J Immunol* 166, 5168-75 (2001)
102. Craggs RI, HD Webster: Ia antigens in the normal rat nervous system and in lesions of experimental allergic encephalomyelitis. *Acta Neuropathol* 68, 263-72 (1985)

## Antigen presentation in EAE

103. Matsumoto Y, N Hara, R Tanaka, M Fujiwara: Immunohistochemical analysis of the rat central nervous system during experimental allergic encephalomyelitis, with special reference to Ia-positive cells with dendritic morphology. *J Immunol* 136, 3668-76 (1986)
104. Matsumoto Y, M Fujiwara: *In situ* detection of class I and II major histocompatibility complex antigens in the rat central nervous system during experimental allergic encephalomyelitis. An immunohistochemical study. *J Neuroimmunol* 12, 265-77 (1986)
105. McCombe PA, BW Fordyce, J de Jersey, G Yoong, MP Pender: Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: an immunocytochemical and flow cytometric study. *J Neurol Sci* 113, 177-86 (1992)
106. McCombe PA, J de Jersey, MP Pender: Inflammatory cells, microglia and MHC class II antigen-positive cells in the spinal cord of Lewis rats with acute and chronic relapsing experimental autoimmune encephalomyelitis. *J Neuroimmunol* 51, 153-67 (1994)
107. Stampachiachiere B, L Aloe: Differential modulatory effect of NGF on MHC class I and class II expression in spinal cord cells of EAE rats. *J Neuroimmunol* 169, 20-30 (2005)
108. Nikodemova M, JJ Watters, SJ Jackson, SK Yang, ID Duncan: Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)alpha/betaII. *J Biol Chem* 282, 15208-16 (2007)
109. Linker RA, E Rott, HH Hofstetter, T Hanke, KV Toyka, R Gold: EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. *Neurobiol Dis* 19, 218-28 (2005)
110. Linker RA, M Sendtner, R Gold: Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice. *J Neurol Sci* 233, 167-72 (2005)
111. Njenga MK, PD Murray, D McGavern, X Lin, KM Drescher, M Rodriguez: Absence of spontaneous central nervous system remyelination in class II-deficient mice infected with Theiler's virus. *J Neuropathol Exp Neurol* 58, 78-91 (1999)
112. Karandikar NJ, CL Vanderlugt, JA Bluestone, SD Miller: Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. *J Neuroimmunol* 89, 10-8 (1998)
113. Perrin PJ, CH June, JH Maldonado, RB Ratts, MK Racke: Blockade of CD28 during *in vitro* activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. *J Immunol* 163, 1704-10 (1999)
114. Girvin AM, MC Dal Canto, L Rhee, B Salomon, A Sharpe, JA Bluestone, SD Miller: A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. *J Immunol* 164, 136-43 (2000)
115. Miller SD, CL Vanderlugt, DJ Lenschow, JG Pope, NJ Karandikar, MC Dal Canto, JA Bluestone: Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. *Immunity* 3, 739-45 (1995)
116. Chang TT, C Jabs, RA Sobel, VK Kuchroo, AH Sharpe: Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. *J Exp Med* 190, 733-40 (1999)
117. Hurwitz AA, TJ Sullivan, MF Krummel, RA Sobel, JP Allison: Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. *J Neuroimmunol* 73, 57-62 (1997)
118. Issazadeh S, V Navikas, M Schaub, M Sayegh, S Khoury: Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis *in vivo*. *J Immunol* 161, 1104-12 (1998)
119. Karandikar NJ, CL Vanderlugt, T Eagar, L Tan, JA Bluestone, SD Miller: Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis. *J Immunol* 161, 192-9 (1998)
120. Mack CL, CL Vanderlugt-Castaneda, KL Neville, SD Miller: Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis. *J Neuroimmunol* 144, 68-79 (2003)
121. Pender MP, KB Nguyen, PA McCombe, JF Kerr: Apoptosis in the nervous system in experimental allergic encephalomyelitis. *J Neurol Sci* 104, 81-7 (1991)
122. Pender MP, PA McCombe, G Yoong, KB Nguyen: Apoptosis of alpha beta T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: its possible implications for recovery and acquired tolerance. *J Autoimmun* 5, 401-10 (1992)
123. Schmied M, H Breitschopf, R Gold, H Zischler, G Rothe, H Wekerle, H Lassmann: Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. *Am J Pathol* 143, 446-52 (1993)
124. McCombe PA, I Nickson, Z Tabi, MP Pender: Apoptosis of V beta 8.2+ T lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. *J Neurol Sci* 139, 1-6 (1996)

## Antigen presentation in EAE

125. Bohatschek M, CU Kloss, K Pfeffer, H Bluethmann, G Raivich: B7.2 on activated and phagocytic microglia in the facial axotomy model: regulation by interleukin-1 receptor type 1, tumor necrosis factor receptors 1 and 2 and endotoxin. *J Neuroimmunol* 156, 132-45 (2004)
126. Bechmann I, S Peter, M Beyer, U Gimsa, R Nitsch: Presence of B7--2 (CD86) and lack of B7--1 (CD 80) on myelin phagocytosing MHC-II-positive rat microglia is associated with nondestructive immunity *in vivo*. *Faseb J* 15, 1086-8 (2001)
127. Kwizdzinski E, LK Mutlu, AD Kovac, J Bunse, J Goldmann, J Mahlo, O Aktas, F Zipp, T Kamradt, R Nitsch, I Bechmann: Self-tolerance in the immune privileged CNS: lessons from the entorhinal cortex lesion model. *J Neural Transm Supp* 129-49 (2003)
128. Remington LT, AA Babcock, SP Zehntner, T Owens: Microglial recruitment, activation, and proliferation in response to primary demyelination. *Am J Pathol* 170, 1713-24 (2007)
129. Lee KM, E Chuang, M Griffin, R Khattri, DK Hong, W Zhang, D Straus, LE Samelson, CB Thompson, JA Bluestone: Molecular basis of T cell inactivation by CTLA-4. *Science* 282, 2263-6 (1998)
130. Takahashi T, T Tagami, S Yamazaki, T Uede, J Shimizu, N Sakaguchi, TW Mak, S Sakaguchi: Immunologic self-tolerance maintained by CD25 (+)CD4 (+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J Exp Med* 192, 303-10 (2000)
131. Bluestone JA, Q Tang: How do CD4+CD25+ regulatory T cells control autoimmunity? *Curr Opin Immunol* 17, 638-42 (2005)
132. Horwitz DA, SG Zheng, JD Gray: Natural and TGF-beta-induced Foxp3 (+)CD4 (+) CD25 (+) regulatory T cells are not mirror images of each other. *Trends Immunol* 29, 429-35 (2008)
133. Curotto de Lafaille MA, JJ Lafaille: Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? *Immunity* 30, 626-35 (2009)
134. Hori S, S Sakaguchi: Foxp3: a critical regulator of the development and function of regulatory T cells. *Microbes Infect* 6, 745-51 (2004)
135. Zheng SG, JH Wang, W Stohl, KS Kim, JD Gray, DA Horwitz: TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. *J Immunol* 176, 3321-9 (2006)
136. Read S, R Greenwald, A Izcue, N Robinson, D Mandelbrot, L Francisco, AH Sharpe, F Powrie: Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function *in vivo*. *J Immunol* 177, 4376-83 (2006)
137. Jain N, H Nguyen, C Chambers, J Kang: Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. *Proc Natl Acad Sci U S A* 107, 1524-8 (2010)
138. Chitnis T, SJ Khoury: Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. *J Allergy Clin Immunol* 112, 837-49; quiz 850 (2003)
139. Gerritse K, JD Laman, RJ Noelle, AA Ruffo, JA Ledbetter, WJ Boersma, E Claassen: CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. *Proc Natl Acad Sci U S A* 93, 2499-504 (1996)
140. Becher B, BG Durell, AV Miga, WF Hickey, RJ Noelle: The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. *J Exp Med* 193, 967-74 (2001)
141. Liang SC, YE Latchman, JE Buhlmann, MF Tomczak, BH Horwitz, GJ Freeman, AH Sharpe: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. *Eur J Immunol* 33, 2706-16 (2003)
142. Magnus T, B Schreiner, T Korn, C Jack, H Guo, J Antel, I Ifergan, L Chen, F Bischof, A Bar-Or, H Wiendl: Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. *J Neurosci* 25, 2537-46 (2005)
143. Carter LL, MW Leach, ML Azoitei, J Cui, JW Pelker, J Jussif, S Benoit, G Ireland, D Luxenberg, GR Askew, KL Milarski, C Groves, T Brown, BA Carito, K Percival, BM Carreno, M Collins, S Marusic: PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. *J Neuroimmunol* 182, 124-34 (2007)
144. Wang C, Y Li, TM Proctor, AA Vandenbark, H Offner: Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. *J Neurosci Res* 88, 7-15 (2010)
145. Dong C, AE Juedes, UA Temann, S Shresta, JP Allison, NH Ruddle, RA Flavell: ICOS co-stimulatory receptor is essential for T-cell activation and function. *Nature* 409, 97-101 (2001)
146. Rottman JB, T Smith, JR Tonra, K Ganley, T Bloom, R Silva, B Pierce, JC Gutierrez-Ramos, E Ozkaynak, AJ Coyle: The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. *Nat Immunol* 2, 605-11 (2001)
147. Liu YJ: Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. *Cell* 106, 259-62 (2001)
148. Liu K, GD Victora, TA Schwickert, P Guermonprez, MM Meredith, K Yao, FF Chu, GJ Randolph, AY

## Antigen presentation in EAE

- Rudensky, M Nussenzweig: *In vivo* analysis of dendritic cell development and homeostasis. *Science* 324, 392-7 (2009)
149. McMenamin PG: Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. *J Comp Neurol* 405, 553-62 (1999)
150. McMenamin PG, RJ Wealthall, M Deverall, SJ Cooper, B Griffin: Macrophages and dendritic cells in the rat meninges and choroid plexus: three-dimensional localisation by environmental scanning electron microscopy and confocal microscopy. *Cell Tissue Res* 313, 259-69 (2003)
151. McMahon EJ, SL Bailey, SD Miller: CNS dendritic cells: critical participants in CNS inflammation? *Neurochem Int* 49, 195-203 (2006)
152. Israelsson C, H Bengtsson, A Lobell, LN Nilsson, A Kylberg, M Isaksson, H Wootz, L Lannfelt, K Kullander, L Hillered, T Ebendal: Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. *Eur J Neurosci* 31, 852-63 (2010)
153. Serafini B, S Columba-Cabezas, F Di Rosa, F Aloisi: Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. *Am J Pathol* 157, 1991-2002 (2000)
154. Fischer HG, G Reichmann: Brain dendritic cells and macrophages/microglia in central nervous system inflammation. *J Immunol* 166, 2717-26 (2001)
155. Bailey SL, B Schreiner, EJ McMahon, SD Miller: CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4<sup>+</sup> T (H)-17 cells in relapsing EAE. *Nat Immunol* 8, 172-80 (2007)
156. Zozulya AL, S Ortler, J Lee, C Weidenfeller, M Sandor, H Wiendl, Z Fabry: Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. *J Neurosci* 29, 140-52 (2009)
157. Greter M, FL Heppner, MP Lemos, BM Odermatt, N Goebels, T Laufer, RJ Noelle, B Becher: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. *Nat Med* 11, 328-34 (2005)
158. Menges M, S Rossner, C Voigtlander, H Schindler, NA Kukutsch, C Bogdan, K Erb, G Schuler, MB Lutz: Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. *J Exp Med* 195, 15-21 (2002)
159. Zozulya AL, BD Clarkson, S Ortler, Z Fabry, H Wiendl: The role of dendritic cells in CNS autoimmunity. *J Mol Med* 88, 535-44 (2010)
160. Adler HS, K Steinbrink: Tolerogenic dendritic cells in health and disease: friend and foe! *Eur J Dermatol* 17, 476-91 (2007)
161. Mueller DL: Mechanisms maintaining peripheral tolerance. *Nat Immunol* 11, 21-7 (2010)
162. Hackstein H, AW Thomson: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. *Nat Rev Immunol* 4, 24-34 (2004)
163. Morelli AE, AW Thomson: Tolerogenic dendritic cells and the quest for transplant tolerance. *Nat Rev Immunol* 7, 610-21 (2007)
164. Sakurai K, JP Zou, JR Tschetter, JM Ward, GM Shearer: Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. *J Neuroimmunol* 129, 186-96 (2002)
165. Kiefer R, T Schweitzer, S Jung, KV Toyka, HP Hartung: Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation. *J Neuropathol Exp Neurol* 57, 385-95 (1998)
166. Ledebroer A, A Wierinckx, JG Bol, S Floris, C Renardel de Lavalette, HE De Vries, TK van den Berg, CD Dijkstra, FJ Tilders, AM van dam: Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. *J Neuroimmunol* 136, 94-103 (2003)
167. Bulloch K, MM Miller, J Gal-Toth, TA Milner, A Gottfried-Blackmore, EM Waters, UW Kaunzner, K Liu, R Lindquist, MC Nussenzweig, RM Steinman & BS McEwen: CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. *J Comp Neurol* 508, 687-710 (2008)
168. Serafini B, B Rosicarelli, R Magliozzi, E Stigliano, E Capello, GL Mancardi, F Aloisi: Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. *J Neuropathol Exp Neurol* 65, 124-41 (2006)
169. Busshoff U, A Hein, A Iglesias, R Dorries, A Regnier-Vigouroux: CD1 expression is differentially regulated by microglia, macrophages and T cells in the central nervous system upon inflammation and demyelination. *J Neuroimmunol* 113, 220-30 (2001)
170. Carson MJ, CR Reilly, JG Sutcliffe, D Lo: Mature microglia resemble immature antigen-presenting cells. *Glia* 22, 72-85 (1998)
171. Dominguez PM, C Ardavin: Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. *Immunol Rev* 234, 90-104 (2010)

## Antigen presentation in EAE

172. Geissmann F, MG Manz, S Jung, MH Sieweke, M Merad, K Ley: Development of monocytes, macrophages, and dendritic cells. *Science* 327, 656-61 (2010)

173. King IL, TL Dickendesher, BM Segal: Circulating Ly-6C<sup>+</sup> myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. *Blood* 113, 3190-7 (2009)

174. Mosialos G, M Birkenbach, S Ayehunie, F Matsumura, GS Pinkus, E Kieff, E Langhoff: Circulating human dendritic cells differentially express high levels of a 55-kd actin-bundling protein. *Am J Pathol* 148, 593-600 (1996)

175. Ross R, H Jonuleit, M Bros, XL Ross, S Yamashiro, F Matsumura, AH Enk, J Knop, AB Reske-Kunz: Expression of the actin-bundling protein fascin in cultured human dendritic cells correlates with dendritic morphology and cell differentiation. *J Invest Dermatol* 115, 658-63 (2000)

176. Al-Alwan MM, G Rowden, T D. Lee, KA West: Fascin is involved in the antigen presentation activity of mature dendritic cells. *J Immunol* 166, 338-45 (2001)

**Key Words:** microglia, dendritic-cells, MHC, EAE, T-cell, neuroimmunology, tolerance, CNS, Review

**Send correspondence to:** Bernardo Castellano, Unit of Histology, Department of Cell Biology, Physiology and Immunology, Institute of Neuroscience. Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain, Tel: 34935811875, Fax: 34935812392, E-mail: [bernardo.castellano@uab.cat](mailto:bernardo.castellano@uab.cat)

<http://www.bioscience.org/current/vol16.htm>